DocGo Inc. (DCGO) Earnings Call Transcript & Summary
February 28, 2024
Earnings Call Speaker Segments
Mike Cole
executiveThank you, operator. Ahead of turning the call over to management, I want to make a few remarks regarding forward-looking statements. Anything said on this conference call that does not describe a historical fact qualifies as a forward-looking statement. Words like may, will, plan, potential, could, goal, outlook, design, anticipate, aim, believe, estimate, expect, intend, guidance, confidence, target, and project, as well as similar expressions, may be used to identify these forward-looking statements. Forward-looking statements of this kind are not a guarantee of future performance, and we cannot assure you that our plans, intentions, outcomes, results or expectations will be achieved or realized. Statements about the future by nature come with meaningful risks, unknowns, and assumptions—lots of them outside our control—and those could make what actually happens, or when it happens, turn out very differently from what such statements describe. Among these risks, unknowns, and assumptions are the ones covered in our risk factors and other sections of DocGo's annual report on Form 10-K, its quarterly reports on Form 10-Q, and additional reports and statements DocGo has filed with the SEC, which you should look at. What actually occurs and what we achieve, or when our outcomes occur, may end up materially different from anything these forward-looking statements say or suggest. Also, today's call includes references to non-GAAP financial measures. You can find reconciliations from these non-GAAP financial measures to the closest comparable GAAP figures either directly in this call or in the earnings release we've posted on docgo.com and filed with the Securities and Exchange Commission. Everything shared on this call is accurate only as of the date we're discussing. Investors shouldn't assume these statements will still hold true or apply later on. We're under no obligation to update anything discussed here to reflect events or circumstances arising after today's call, or to reflect new information or unanticipated events, unless the law requires it. With that. Mr. Lee Bienstock, DocGo's chief executive, is next and has the floor. Over to you, Lee.
Lee Bienstock
executiveThank you, Mike, and thanks to everyone for being here today. You could definitely say that 2023 was a year full of activity, and during my first hundred days as CEO, my attention was sharply fixed on establishing a bold vision for how we will take proactive steps to help patients become healthier and to help them avoid hospitalization. The record results we posted for Q4 and for the full year demonstrate that this vision is coming to life, and I'm eager to keep building on that momentum in 2024 and beyond. This quarter brought significant expansion and dependable operational delivery, and we made real strides toward our main strategic goals in each of our three core customer segments: insurance partners, hospital systems, and government population health programs. I'll walk through what we achieved and how we're progressing in each of those segments, but I'd like to begin with the financial results and our outlook for 2024. For Q4, revenue and adjusted EBITDA reached $199.2 million and $22.6 million, respectively — gains of 83% and 232% over the fourth quarter of 2022. Just in that quarter, DocGo handled more than 72,000 mobile health interactions and 190,000 medical transports around the world, supported by a team that has grown past 8,000 people. Our growth isn’t limited to scale—it also covers breadth. Over the past year, we’ve more than doubled what we offer, adding services such as bone density scans, depression screenings, and other useful offerings we can provide conveniently beyond the conventional brick-and-mortar healthcare system. Though more work remains, we achieved meaningful improvement in cash collections late in the fourth quarter, and that momentum has accelerated in 2024. Since the year ended, we've brought in roughly $120 million of outstanding receivables, and we're collaborating with our biggest customers to set up a steadier rhythm moving forward; we're also getting to a more mature stage with certain recent municipal and population health initiatives, and the elevated costs tied to launching those programs are now easing; that leaves us in a strong position to deliver better adjusted EBITDA margins and cash flow as we progress through 2024. Along those lines, we revised our 2024 revenue guidance today to a range of $720 million to $750 million; that matches the view we shared earlier, which indicated 2024 revenue would come in above $700 million. For 2024, we expect adjusted EBITDA to land between $80 million and $85 million. We also announced recently that a share repurchase program of as much as $36 million has been approved. DocGo has confidence in its cash position, in its cash collections, in its access to capital, and in the strength of its business fundamentals. Given where the stock trades today, we see buybacks as an efficient way to use capital that enhances value. Since I became CEO, I have focused our work on our core customers, our insurance partners, hospital systems, and government population health programs. Now I would like to walk through the progress and growth across all three. To start with one area that’s comparatively modest—it doesn’t account for much revenue at present—but in our view has huge room to grow: the care gap closure programs we run alongside large insurers. These efforts initially center on patients who aren’t compliant, meaning they haven’t visited their primary care provider in more than a year and have at least one chronic condition. Through our mobile capabilities, reaching patients where they are and delivering care into their homes, we’re demonstrating to those customers that patient compliance rates can be improved substantially. At this point we provide more than 30 distinct care gap closure services, such as colon cancer screenings and diabetic retinal exams. Toward the end of 2023, we launched payer programs across Michigan, Connecticut and New Jersey. In Q4 by itself, the number of patients we served through those programs was more than twice what it had been in Q3, and we anticipate that momentum will continue. The fact is, a portion of the population either avoids or is unable to reach a conventional brick-and-mortar site for these services. When we make the experience highly convenient and efficient within patients' own homes, we're able to enhance health outcomes, reduce costs, assist with stratifying risk and help prevent hospital stays — exactly what our insurance partners are after. And naturally, it's what patients want too. Things are also moving forward on the remote patient monitoring side. At present, we're monitoring about 50,000 patients with CIEDs — that's Cardiac Implantable Electronic Devices — compared with 38,000 when 2023 began. We keep seeing a substantial opportunity in these monitoring efforts, whether standing alone or as part of improving our HEDIS quality scores and our value-based service offerings. Turning to the Medical Transportation segment, which consists mostly of hospital systems, we finished the year with yet another solid showing. For context on how far this has come: during Q4 of 2023, the business was running at a revenue run rate of $160 million, with gross margin at 28.9%. At the close of the year, that run rate stood at $190 million, with gross margin at 37.5%. During the second half of 2023, we announced several meaningful RFP wins, both in the domestic market and in the UK, and we expect those to keep contributing to strong growth in 2024. We've also put considerable emphasis on cross-selling and on expanding our Mobile Health presence alongside our hospital system partners, and we expect that effort to start producing benefits later in the year. And third, in the government RFP channel, we currently run population health programs in Arizona, California, Michigan and Tennessee, in addition to New York. These are great chances for us to demonstrate what our offering is worth and to expand in those regions over time, in much the same way we've already succeeded in the northeast. Through our work with asylum seeker communities in New York, we've been able to widen and improve the services DocGo offers. That covers growing our behavioral health services by finishing over 50,000 depression screenings, expanding our mobile pharmacy to the point where it can prescribe more than 70 different kinds of medications, and increasing our ability to give vaccines of over 40 different types. We'll continue to expand what we can do and use this institutional knowledge and experience to create valuable new programs for both existing and prospective customers. Here's a powerful statistic that demonstrates the value we provide. Our estimate is that in 2023, through our different programs, we avoided over 54,000 needless ER trips and generated savings exceeding $167 million in healthcare costs for our partners and the patients they treat — showing how beneficial DocGo's influence can be for those partners and, arguably more significantly, for the communities we serve. Our business's scope and effect extend far past underserved groups like the homeless and asylum seekers. For hundreds of hospitals we provide Medical Transportation, in several states we operate vaccination programs, we keep watch on tens of thousands of cardiac patients, we bridge care gaps for chronically ill, bedbound people, and much more. To wrap up, the goal we set for ourselves remains the same: delivering medical care to individuals at the moment and location they require it. During 2023 we provided that to several hundred thousand patients representing every segment of society, all in service of keeping them from needing hospital admission, and the results of this work are highly encouraging. With that, I'll turn things over to Norm, our CFO, who will walk through the numbers for Q4 as well as the entirety of 2023. Norm, over to you.
Norman Rosenberg
executiveThanks, Lee, and good afternoon, everyone. For the fourth quarter of 2024, total revenue came in at $199.2 million, representing a 7% rise versus the prior quarter and an 83% jump compared with the fourth quarter of 2022; across the full year, total revenue reached $624.2 million, landing at the top of our upwardly revised guidance range and exceeding full year 2022 revenues of $440.5 million by more than 40%. Mobile Health revenue in the fourth quarter of 2023 totaled $150.4 million, 8% above the third quarter and over twice the level seen in the fourth quarter of 2022. Growth came from a number of projects, business lines and geographies. In the fourth quarter of 2023, Medical Transportation revenue climbed to $48.8 million, which was 32% higher than the transport revenues reported for Q4 of 2022. Almost every transportation market saw year-over-year revenue growth, carrying forward the momentum that began in the latter half of last year. Over the past six quarters in a row, transport revenues have increased sequentially, and they have more than doubled during that period. Mobile Health revenues accounted for approximately 75% of total revenues in the fourth quarter, with transport supplying the other 25%; we expect Mobile Health to continue delivering roughly 75% of total revenue in 2024. Net income in Q4 2023 was $8 million, versus net income of $4.6 million in the third quarter and net income of $7.1 million in the fourth quarter of 2022. That comparison reflects a tax benefit of $9.1 million in the fourth quarter of 2022 tied to the release of a valuation allowance for net operating losses. For the full year, net income was $10 million, compared with $30.7 million in 2022. Two line items explain the year-over-year decline in net income: non-cash stock compensation expense and income tax expense. We have broadened our stock compensation program to cover a wider group of managers, so that more colleagues who drive strategy and execution have incentives to maximize shareholder value. Regarding taxes: during 2022, we recognized a benefit of roughly $9 million after freeing up the valuation allowance tied to our net operating loss carryforwards, or NOLs, once pre-tax income began to appear and those NOLs could be realized. Then in 2023, we booked income tax expense as those federal NOL carryforwards were consumed by generating pre-tax income. For the fourth quarter, our effective tax rate came in at about 35%, and we consider that a sensible assumption going forward. Fourth-quarter 2023 adjusted EBITDA reached $22.6 million, which is 35% higher than the $16.7 million posted in the third quarter and more than triple the $6.8 million recorded in the fourth quarter of last year. For the entire year, adjusted EBITDA reached $54 million, up 31% from $41.3 million in 2022, and it was over twice the adjusted EBITDA we reported in 2021. Our adjusted EBITDA margin for Q4 was 11.4%, versus 8.9% in Q3 and 6.3% in the fourth quarter of 2022. That Q4 adjusted EBITDA margin actually stands as our highest since Q1 of 2022 — a time when close to one-third of total company revenues came from mass COVID testing services that carried relatively high margins. For Q4 2023, total gross margin came in at 33.5%. That's a solid gain versus the 29.5% we reported in Q3, but it trails the 39% gross margin we had in Q4 2022. Q4 2023 ended up being the strongest margin quarter of the year, slightly ahead of Q2. The fourth-quarter gross margin represented a healthy bounce back from the weak levels in Q3, which had taken a hit from higher costs tied to the recent launch and ramp-up of new projects. In Q4, we not only held revenue at Q3 levels but actually increased it, while also getting overtime and subcontracted labor expenses nearer to planned levels, which helped us improve margins. With these projects now running smoothly, the first two months of 2024 have brought additional gains in those areas, and we expect some sequential gross margin improvement in Q1 of 2024. Mobile Health segment gross margins came in at 32.2% during Q4 of 2023, compared with 28.8% in Q3 and 43.9% in Q4 of '22, a quarter that had gained from certain one-time high-margin revenue streams. Turning to Transportation, gross margin continued to widen—reaching 37.4% in Q4 2023, compared with 31.7% in the third quarter and 29.4% in Q4 2022. That marks six straight quarters of gross margin expansion in Transportation, which has come together with the sequential revenue gains I noted earlier, driven by scale benefits, better utilization, less pressure from wages and fuel prices, a richer mix of trips, and our ongoing move toward leased hour programs that carry higher margins. Now on operating costs: SG&A equaled 27.6% of total revenues in the fourth quarter of 2023, versus 24.8% in the third quarter, and was well below the 38.1% posted in the fourth quarter of 2022. With revenue climbing during the latter half of 2023, SG&A came down as a share of overall revenue, which drove operating margin expansion. Beyond that, we routinely examine our cost structure looking for efficiency opportunities, especially among non-field headcount. In Q1 of 2024, we carried out a targeted reduction in force, producing some savings that will be captured as we move into Q2 and beyond. Now to the balance sheet. At December 31st, 2023, total cash and cash equivalents, including restricted cash, stood at $72.2 million, versus $67.3 million at the close of Q3. Receivables continued to rise, reflecting the revenue surge we experienced over the final six months of 2023. The force behind that receivables growth is our government segment, where the initial payment cycle runs very long, as we have noted before. Still, as Lee said earlier, during Q4 we started getting paid for that work, and those payments have picked up speed since the start of the New Year. A large share of the receivables we carried at year end has now come in over recent weeks. Take our engagement with New York City’s Department of Housing Preservation and Development, or HPD: as of today, we have brought in close to 80% of the year end 2023 receivables tied to that project, and we are nearly caught up on it. As we keep bringing that receivable down, we believe near term collections will be sufficient to lift our total cash balance in later periods, even with the working capital we continue to need as we expand. Thanks to the recent collections, we have reduced the amounts outstanding on our credit line, and the balance outstanding right now stands at zero. Moving to guidance and our outlook for 2024, we expect demand from our customers to stay strong for both Mobile Health and Transportation Services. Our forecast puts 2024 revenues between $720 million and $750 million. We anticipate quarterly revenues across the year that look like the levels from Q3 of 2023. Any expected drop in migrant related revenues during the second half is projected to be offset by new programs plus growth elsewhere. We expect gross margins above full year 2023 levels, much closer to what we saw in Q4. Adjusted EBITDA should land between $80 million and $85 million, and adjusted EBITDA margins should sit solidly in the double-digit area. For the full year 2024, we expect adjusted EBITDA margins to be 250 to 300 basis points above the adjusted EBITDA margins we recorded across full year 2023. Lastly, we expect cash flow from operations of $65 million to $75 million in 2024. With that, I would like to hand the call back to the operator for Q&A. Operator, please go ahead.
Ryan MacDonald
analystHello, and thank you for taking my questions. Congratulations on such a robust quarter and a solid outlook for ’24. Lee, it’s wonderful to hear about all the wins and the latest update regarding the three end-market priorities. As you consider and review the pipeline for 2024, in which of them—payers, health systems, or the government channel—are you feeling the greatest optimism? And how do you think that optimism will show up in the revenue mix among those three segments for ’24?
Lee Bienstock
executiveHi Ryan, I really appreciate the question. It’s good to talk with you. I feel positive about all three. Our hospital-system pipeline is quite robust, covering both Medical Transportation and additional Mobile Health possibilities, and I believe those will keep fueling our expansion with hospital systems. I remain consistently hopeful about what we are doing in the municipal arena as well. I noted many of the fresh geographies we concentrated on heavily during 2023; we will keep submitting 100 RFPs during this year, and I expect our win rate to remain steady across this year as we pursue opportunities. I believe those first two areas—hospital systems and our municipal work—are going to keep fueling a lot of this year's growth. Beyond that, I'm genuinely optimistic and excited about what we're doing with our insurance partners. That will probably remain the smaller portion of the business, though it may well be the fastest-growing one. I expect it to pay off in the later months and on into 2025 and beyond. We're building a truly strong foundation with those insurance partners, since together we can deliver results for our patients with them, help close care gaps, and really reach patients who haven't been to a doctor in more than a year. The early results here have been genuinely encouraging, so I expect you'll see us broaden this effort, and I also expect those relationships to keep evolving. We've completed our first partnership — and there are more in the pipeline — under which we'll share risk together with our insurance partner. That means when we bring total cost down and when we play a part in achieving better health outcomes, we earn a return for doing so, and that has us quite enthusiastic as well, since we believe the chance to deliver on that is a really strong one. To respond straight to what you asked: all three leave us quite hopeful. In 2024, the first two should keep serving as the main growth engines, though we are building a very solid base, and with our insurance partners that growth will become visible across 2024 and afterward.
Ryan MacDonald
analystThat's genuinely useful context, Lee — appreciate it. For my follow-up, maybe this one's for Norm. I'm quite struck by how large the margin improvement is that's baked into the early outlook for fiscal '24. It sounds like a decent chunk of that gross margin gain is sustainable, but perhaps we could dig into that a bit — I believe it implies 250 basis points of adjusted EBITDA margin expansion at the midpoint in '24. How do you see the split between gross margin improvement and further OpEx efficiency?
Norman Rosenberg
executiveSure, Ryan. There's also a math piece to this, since we exited the year at roughly 11.5% EBITDA margin, versus about 8.5% to 9% for the full year. What that really means is we anticipate holding onto the operating leverage we picked up later in the year. Likewise, we believe the gross margin improvements from Q4 versus Q3 will carry forward. So if we just — if we ended up seeing the kind of EBITDA margins we posted in Q4 throughout the year, that gets you the 250 to 300 basis points of improvement; and here and there, we do see some spots where we expect a bit of extra improvement as things progress. We simply don't want to run too far ahead of ourselves when it comes to what we assume on gross margin.
Ryan MacDonald
analystThanks for that remark —
Norman Rosenberg
executiveWe came out of the year running at a solid pace. I mean, that accounted for a substantial share of it.
David Larsen
analystHello, and congratulations on the quarter. Could you perhaps elaborate on those value-based care hires you referenced in the press release? In my view, it looks like DocGo is very well positioned to serve the managed care plans. Having data systems like many health tech companies do is great, but actually putting them to use is a different matter; and from what I can see, you appear to be heading in the right direction — a bit more clarity there would be helpful. Thanks so much.
Lee Bienstock
executiveAbsolutely. Hello, David. I truly appreciate that question. So our talent pool keeps growing. We brought in some truly remarkable people during the back half of 2023. You mentioned Yong, who came aboard as our VP of our Payer Program; so he's really heading up that business segment alongside our Chief Product Officer and others in the space, as well as our CEO of our Clinical Practice Group, Dr. Powell. We're truly assembling a fantastic team there with abundant, deep expertise. And Yong comes to us straight from CVS. That's CVS Health, so truly excellent experience, and he will be instrumental in helping us build that business. We also strengthened our government program business with a terrific hire, Jen, who previously served as Chief Operating Officer of City Harvest. And so our team keeps growing. We have a fantastic, fantastic team, a hardworking team, a truly intelligent team, individuals with diverse points of experience, and they're genuinely helping us develop the programs. And as you noted, our value-based arrangements are something we're especially thrilled about, since we genuinely believe our tech platform — which helps us optimize the right clinician in the right vehicle, with the right tools, with the right tech in a patient's home — and making care far more accessible, we believe, will truly drive better health outcomes, and we're watching that unfold. And clearly, as patients' health gets better, the cost for the overall system and the cost for our insurance partners comes down; and so it's this fantastic experience for the patient where we deliver care to them. We also help them get much healthier, and then everyone benefits in that scenario. And so we're extremely, extremely excited about it. It truly lets us leverage our mobile capabilities that we've developed now over 8 years. This lets us make use of the technology platform that has assisted us in optimizing how the nearly 1,000 vehicles we run each day across the US and the UK are routed, and then lets us deliver care in innovative ways together with our excellent clinicians and our Clinical’s Practice Group to truly drive improved health outcomes for communities; and we are seeing that unfold in several states at this point; so we are eager to keep investing in that area, we are eager to keep our focus there, and we believe that as we move into more and more value-based arrangements, we see substantial opportunity for us in that space.
David Larsen
analystGreat, thank you very much. Now, regarding the City of New York deal — that migrant services component — if it's running at $300 million a year at its peak, what do you expect for, let's say, the back half of ‘24 and going into 2025? Would that become something like $150 million? In my view, that would be fine; it's been a bit of a drag on resources, so to speak. Any additional thoughts on that would be really helpful. Thank you.
Lee Bienstock
executiveAbsolutely; so as the year moves along, we've built in a moderating level of revenue from the asylum seeker work; through the quarters of 2024, asylum seeker revenue will ease and decline as the year moves along. And then, naturally, other programs and other investments we're making and other customers we're growing with are going to take its place; that's how we built out the year. That's how we got to our guidance. We were — we were very deliberate about the guidance we're providing; we have line of sight, as you know that's how we set our guidance. That's basically how we took everything into account. As Norm said, we expect quarterly revenue to be fairly in line with what we recorded in Q3 of '23, and it should remain more or less steady over the course of this year. After that, as I noted, revenue tied to migrants will gradually wind down while other projects fill the gap. On 2025 — thanks for the ER <<inaudible>> on that — we'll share more details about 2025 once we're nearer to it.
David Larsen
analystGreat, thanks. Congrats on a good quarter.
Lee Bienstock
executiveThanks.
Michael Latimore
analystThank you. Yeah, congratulations on the quarter. I really liked that stat about the number of ER visits prevented. That was excellent. So just regarding the guidance a little, should we assume the EBITDA margin stays similar each quarter, or does it grow as the year goes on? And then as for the new business that will fill in for the declining migraine care, is that business you've already won, or is some of it something you have to go out and win?
Norman Rosenberg
executiveWell, Mike, this is Norm. I'll take that first one. I think what you saw in terms of the EBITDA margin, which we broke out for Q4, is a pretty good proxy to use as we go through the quarters. Realistically, you're going to have some quarters a little bit higher, a little bit lower, and there's going to be a mix of where the gross margin goes versus the SG&A percentage, but essentially it should be pretty consistent throughout the year.
Lee Bienstock
executiveAnd then — hi, Mike. On the pipeline and revenue question: every bit of revenue we're currently looking at for this year comes from customers we already have or projects we've already won. And naturally, we're submitting new RFPs each week. Growing our sales pipeline is something we work on daily. So as new things arrive, those will give us additional opportunities.
Michael Latimore
analystGreat. And where do you expect the number of employees to go during this year? What figure do you anticipate by the end of the year?
Lee Bienstock
executiveYeah, we have a wonderful team. It grew a lot over the course of 2023, and I think our headcount will remain relatively flat this year. I think we've finished building out our team. Our employee count lines up with our revenues from Q3 and Q4, so we really have built out the team. So we feel that our current team size is optimized right now and will stay consistent throughout this year.
Michael Latimore
analystOkay, sounds good. Many thanks.
Sarah James
analystApologies for that. I was hoping to get a bit more detail on the '24 revenue guidance. What shifted between January and now that led to the raise? And could you walk through the mechanics of how you're viewing New York, HPD and the trail down? Mechanically speaking, how does that play out after May? Do you continue operating, or is there a multi-vendor assumption at that stage?
Lee Bienstock
executiveSure. So regarding what has changed since the January revenue. And hi, Sarah — good to hear from you, I should say. Let me begin by thanking you for the question; on the revenue guidance, when we first gave that initial revenue outlook back in January, we indicated revenues would exceed $700 million; we truly wanted to provide a figure we had solid visibility into and felt highly confident about, and at that moment we believed that was very much required. Throughout, we have constructed a model giving us visibility into each of our customers, each of our projects, and all revenue anticipated month by month; we conduct an extremely thorough process involving all our market leaders and all our project leaders to forecast for this year, and then we sit down with every one of them; those meetings were happening at precisely that time. And so as we honed that forecast, as we collaborated with those market leaders who genuinely have strong visibility into the revenue we expect for this year. That is how we have now updated guidance during the call to share, and therefore revised it upward. We shared that it would exceed $700 million; now we are sharing that the range will be $720 million to $750 million. And that is the process we have consistently followed, and we have consistently provided specific guidance precisely on this first call of the year. So we wanted to maintain that cadence.
Sarah James
analystWonderful, and —
Lee Bienstock
executivePlease go ahead, Sarah, go right ahead.
Sarah James
analystNo, no — I was only going to say the question back to you, since it sounds like you already have it.
Lee Bienstock
executiveYes. So regarding HPD, you mean the revenues tied to migrants. Our forecast assumes those migrant-related revenues will ease off as we move through the year. We have several distinct models for the migrant revenues, and we keep assisting the city through the humanitarian crisis. So our projection did include migrant related revenues falling during the back half of the year, and we'll keep providing updates on how that develops over the course of the year.
Sarah James
analystGot it. For my last question, I'd like to zero in on the EBITDA margin guidance. Looking at that range, it kind of implies that at the top end you'd remain at your 4Q level. But with several contracts maturing, that seems almost a little cautious to me. So could you walk through the moving pieces you're factoring into the margin progression from ‘23 to ‘24?
Lee Bienstock
executiveYeah, regarding the EBITDA guide, I think you brought up something really important, which is that as certain projects mature, we're able to optimize them and expand the margins. At the same time, we're weighing those costs against the fresh initiatives we're expanding and the additional investments we're funding—especially within the insurance payer segment, where we're entering new markets and new geographies, adding capabilities, and working to ensure we provide an outstanding patient and customer service experience for the insurance partners we serve. We're putting substantial resources behind that effort: new vehicles, new product features under development, excellent clinicians joining us, significant spending on their training, plus investment in new technologies and devices and the work of integrating them all together. As you noted, we keep expanding the initiatives already in place, and we will remain in a growth posture—continuing to put money into every part of our operations, especially the insurance payer segment. That is the area where you see those EBITDA margins blending together, in a sense.
Sarah James
analystGreat. Thank you.
Richard Close
analystGreat, thanks. Congrats on a solid year. Maybe, Lee, regarding the national payer partnership — that value-based care agreement you announced this morning, the new one — could you give us any further details? Is it merely a pilot? Or is it something like a fixed number of lives, a particular state, any economics you can share concerning the risk component?
Lee Bienstock
executiveYeah; so as the year goes on, we’ll be sharing more and more about these contracts. We really want to make sure we get them off the ground. We already had several of these initiatives underway, and honestly, the starting point is basically aligning what we do with our health plan partners—and we have a lot of them. We've publicly named Elevance, Healthfirst, Emblem, and L.A. Care, and more will be coming. So many of these partners are already engaged with us. As I said, we're operating in various regions. And it truly starts with pinpointing the health plan, pinpointing patients who are difficult to contact, pinpointing patients who haven't been in to see their physician and who live with chronic conditions. Sometimes a patient has multiple chronic conditions. Sometimes we visit a patient knowing they have a single chronic condition, and the health plan's records show the same thing. Yet the visit itself reveals more, since these patients haven't been to their doctor in over a year, and we can spot that they actually have multiple chronic conditions. That naturally improves risk stratification and lets us manage the patient population far more accurately, so this is truly the starting point. We enter the home, we engage the patient, and we close a care gap. That is genuinely where it begins. From there, it develops to the point where we can serve as that patient's primary care provider. Once we take on that primary-care role and can potentially sign them up for RPM and Virtual Care Management, we start receiving their readings—maybe blood pressure daily or every other day, and weight on a similar cadence. With that ongoing visibility into their health, we can step in whenever it’s needed, and that shows how we can genuinely make a substantial difference to that patient’s health. We also need to be thoughtful about how we engage in value-based and risk-sharing deals. That's the lens we use for the market, and it's how we work alongside our payer partners—above all, to help close care gaps. Above all, we're delivering care to patients who previously weren't getting any. Our initial step is assessing each patient's risk level—the RAPS score—and from there we might serve as that individual's primary care provider, with meaningful growth stemming from that.
Richard Close
analystOkay, so as a follow-up, I’m curious what the revenue model looks like for these kinds of arrangements. And on the risk piece — is that something where at year-end you find out how you did, and there’s a lump-sum bonus? I’m just trying to get a clearer sense of exactly how the revenue model works for this business. Obviously it’s small right now, and if you could tell us how large the insurance business is, that would help, but I’m mainly trying to understand that as this business scales over time.
Lee Bienstock
executiveYeah, and that’s a great question. So essentially our arrangements begin as a care gap arrangement. Once we hit a critical mass of patients, we then have the ability to share upside risk only; and clearly the risk quotient — the value sharing — is mitigated in that scenario where we have only upside benefit, and then we have the chance to move into upside — full risk, upside and downside risk. So there’s sort of a gradation there; in terms of the economics, we receive a care gap closure rate when we go into the home or address a care gap virtually. In some cases, we close care gaps, and we’re able to do that virtually when we need to go into the home, we get a care gap rate. And then as we become the primary care provider, as we begin to share risk, we take a percentage of the medical loss ratio, essentially, and those get negotiated with the payer partners, and that’s how that business is structured.
Richard Close
analystAlright. So one last thing for Norm regarding the lease rate model in transportation — could you update us on where lease rate sits as a percentage of transportation revenue, perhaps, in Q4?
Norman Rosenberg
executiveIt's likely still around half of what we do, and in certain markets it may be even less. I think that's an important — it's a good question, and an important point to address, because for quite a while now, probably going back a year and a half, we've discussed how we're kind of phasing out fee-for-service; but something funny happened along the way to phasing it out, which is that within our APCs — which we measure and report on, our average price per trip — and some of the other metrics, such as utilization around the fee-for-service business, things have gotten better. That improvement you've witnessed. The six sequential quarters of margin improvement on the Transport side did not come about so much from the fact that we've done more leased hour than fee-for-service. It came about because fee-for-service has turned into a far more profitable business following a lot of focus, following a lot of things heading in the right direction. So I'd say, again, as we work to negotiate new contracts, we're definitely shifting toward a leased hour model; but from where I sit, the fee-for-service portion of the business will always remain somewhat significant, and it will be a profitable driver of the business. That said, when you look at the margins we saw. It's important to highlight this. If you look at the margins we saw for Transport in Q4 above 37%, I'd say that reflected us performing particularly well. And a couple of things happened that may have given us some outlier margins. I wouldn't claim that's necessarily the run rate of the margin going forward. I think that figure is closer to 34%, 35%, but that's still far, far higher than a year earlier, when it was in the upper 20s. So that's one of those things that will kind of moderate itself as we head into 2024. But the story, on both the revenue side and the margin side for the Transport business, is exceedingly healthy.
Richard Close
analystOkay, thank you very much.
David Grossman
analystThanks. There are a few questions that have already been raised, and I want to follow up on some of them. First off: looking at the Mobile Health business, a quick rough calculation suggests that, once you take out the HPD contract, you're likely assuming growth above 30% for the remainder; so firstly, does that estimate seem roughly correct? And secondly, given that 30% growth assumption, would you say you have fairly solid visibility on it at present? Perhaps you could tell us where that visibility comes from for this sort of non-HPD Mobile growth outlook for '24.
Norman Rosenberg
executiveYeah, hi David — Norm here, and I'll handle that question. First off, I believe that when it comes to our guidance, I'm not sure we see eye to eye on what to expect for how HPD revenues will move. Like Lee mentioned, we certainly anticipate a modest pullback; however, as the year goes on and we near the completion of the contract, we believe the decline won't be quite as sharp as we may have assumed previously. That said, I can't say whether that gets you to 30% growth on the Mobile Health side, though it's clearly a fairly strong growth figure. That will exceed the growth rate for total revenues we've outlined here. So it's going to account for a larger share of the whole; we have fairly solid visibility into it. I mean, there isn't some huge ambitious figure baked in there. Everything we discuss in our 2024 figure is organic. So should we make any acquisitions — which is always possible — that isn't how we'd get there, and I think we have a decent level of visibility into that. I'm viewing it purely from a numbers standpoint. I know, Lee, if you'd like to add anything about what's happening on the ground.
Lee Bienstock
executiveYes, David, I’d say your estimate for how fast the rest of the business will grow falls within the right range. The various components are expanding at varying paces, but as Norm said, our models show migrant revenue going down during the latter half of the year. Meanwhile, additional projects are arriving and will pick up momentum as the year goes on. So I expect the growth rate will stay at the Q3 level we recorded last year, in line with that pattern, and once migrant revenue tapers off, the other incoming items will step in, which clearly will lift the growth rates of those other incoming items.
David Grossman
analystRight. So perhaps a useful angle here, Lee, would be for you to shed a bit more light on what these deals actually look like — specifically the ones sitting in the Mobile pipeline that aren't reflected in the guide — covering the contract types, the timing, and, if possible, the magnitude, so we get a feel for what you're seeing in that pipeline with some of these newer business pieces.
Lee Bienstock
executiveYes, so what we have — the pipeline continues to hold deals and projects much like the ones we've always had. Many of the Medical Transportation deals in that pipeline follow a very similar pattern; they match our leased hour arrangements exactly as they exist today. So we simply keep doing more of those deals. We keep forming more of those partnerships, whether with additional hospital systems or by expanding into more hospitals within the systems we already serve, plus additional locations. So those will carry on; they look just the way they always have for us. We've had success with this; it works. And the contracts perform really well alongside our partners. They line up incentives extremely well. And where municipalities are concerned, it will keep being — well, we're going to grow more and more deliberate on the municipal side, I should mention that. So historically, our municipal projects have involved access to vaccines and infectious disease management. We're seeing more and more of it. We're responding and finding success in health coaching, in bringing access to underserved populations — particularly Medicaid populations and other groups lacking care access in municipalities, places with healthcare deserts. Municipalities have healthcare deserts, and we're helping deliver care there. We've always performed really well in that area. The access we provide has genuinely helped those underserved communities, and we keep seeing success with those projects, and they will continue; we're moving further and further into behavioral healthcare. We've always done that. We've been at it for years, but our capabilities there have really expanded. We now have hundreds of social workers and case workers delivering wonderful services, from depression screenings to other crisis response. And so we're going to keep scaling that. We see plenty of RFP opportunities open in the behavioral health space. That's a field that's growing a great deal, and so I think you'll see additional growth in that area too.
David Grossman
analystOkay, great, thanks. If I may, just one additional question. Norm, looking at your cash flow guidance, it appears the outlook for cash flow from operations sits around $10 million to $15 million under adjusted EBITDA — that might simply be a matter of definition, but I was attempting to understand that dynamic, given what seems like a fairly substantial working capital tailwind you ought to capture from the HPD contract this year.
Norman Rosenberg
executiveSure; let me walk you through it. Obviously, taxes make up the biggest portion of that gap. We're paying taxes now. Our federal NOLs are used up. As we note in the K we filed today, we have substantial state NOLs. Still, we must take into account that going forward we will be a taxpayer, and that explains most of the gap. Naturally, you would add back any non-cash stock comp or depreciation in your calculation; regarding that estimate, however, it presumes a working capital environment that is somewhat neutral. Responding to that, David — there may be some upside there. We've already observed it during Q1 so far, and if some of those working capital shifts from late last year, particularly the second half, end up reversing, that would actually work in our favor. Still, on that assumption — and I want to stress that everyone defines things differently and looks at cash flow in different ways. When I talk about cash flow from operations — the figure you’ll find in our cash flow statements as the year unfolds — what we’ve assumed is working capital moving in a range from neutral to modestly positive across the year. That’s the basis we’ve built in —
Norman Rosenberg
executiveNo, please, go ahead.
Pito Chickering
analystYeah, good afternoon, or good evening. Appreciate you taking my questions. To pose the last questions a bit differently. As I said, if you stepped down for HPD, you'd probably be less than feared. So from a pipeline perspective, do you believe you can grow EBITDA in 2025 without HPD? And when you think about HPD, should we treat it as roughly a $250 million annualized contract with a 30% gross margin as a ballpark?
Norman Rosenberg
executiveYeah, I'd say — this is Norm. I'd say, perhaps a bit lower than that when it comes to run rate, but that's in the general ballpark. The margin is fairly consistent with our overall margin on Mobile Health. Maybe a couple of points lower than some of our other projects, but not materially different one way or the other. But as far as 2025 goes, I can tell you that in terms of our internal planning, we are planning as though that contract or that program doesn't exist. So whatever goals we put out there regarding where we want to be in 2025 or an exit rate for 2025, those remain the internal goals; and the mandate we've given to the folks in the organization here that are going to make that happen is that they have to come up with a model and plan that gets us there without assuming a big chunk of that from HPD.
Pito Chickering
analystOkay, let me put the question a different way. Suppose, in that rough ballpark, I say $60 million of EBITDA. If we model ‘25 without that contract, should we still be relying on today’s guidance and thinking about growth on top of that? Or should we expect a step back before things normalize in ‘25?
Norman Rosenberg
executiveBased on how we’ve modeled it out, we believe it will moderate along a pretty — nothing ever moves in a straight line, but we believe it will moderate along a pretty linear path. And the things we have visibility into would help us sort of fill in those gaps as we reach the end of 2024; I don’t really see a big cliff, right. I think that’s the main point here: as we entered the year, and as we were entering the second half of last year, that potential was always there. I don’t think we really see a cliff. I don’t think it will play out that way. So I think it will be a little more gradual. But there does come a point where we have to assume that it will have to be entirely replaced.
Lee Bienstock
executiveAnd I’d like to add one more point, Pito. I think there’s been a lot of discussion about how our models incorporate migrant-related revenues declining in the second half of the year — and yes, that is in there. But as Norm said, we don’t necessarily expect a cliff. We’re doing everything we can to support our partners, New York City, and again, we’ve worked with them for a number of years and have been running many different population health programs alongside them, including, as of today, programs we operate for unsheltered homeless populations. As for the migrant service, we don’t have a situation where it simply falls off a cliff. Again, we are modeling it as abating, because we prefer to take a conservative approach on that. But I can tell you we’re genuinely proud of the work we’re doing at an enormous scale that we’re able to deliver it at. And we’re doing everything we possibly can to help the city manage the crisis and ultimately help asylum seekers as they arrive, enter the system, and then ultimately exit the system. And we have programs designed to do that. So we’re going to keep helping there; we did take a conservative approach toward the back half of the year, as we’ve been discussing, but there’s no indication at all right now that some cliff exists or that there’s any reason to believe everything is abating toward the back half of the year. Again, that’s the approach we’ve taken, and that’s what you’re hearing us communicate to you on the call, but again, we feel like we’ve modeled that out toward the back half of the year. But again, no indication that necessarily a cliff is coming here, which I want to make sure we’re communicating.
Pito Chickering
analystPerfect. Yeah, when it comes to your <<inaudible>>, your capacity to pivot and adapt your business model has always been extraordinary. I guess the question I keep hearing from investors is around sort of ‘25, worst case scenario, HPD is not there. So I guess let me sort of ask this one more time in a different way, and then I apologize. But, if I think about your ‘24 guidance, if there’s no HPD, are we still thinking about EBITDA growth off of that base in 2025?
Lee Bienstock
executiveYeah, that’s absolutely what we’re modeling right now. And again, we’ll share a lot more about 2025 as we progress through this year; but I can tell you we are focused on executing operationally. We’re always looking for ways to optimize the business. From day one, we’ve operated these projects as profitable projects; we’ve operated the business so that we can expand the business and invest in different areas. And so I can tell you, we’re going to continue to be looking for efficiencies and continuing to expand both revenues, top line and bottom line.
Lee Bienstock
executiveThank you. Thanks to all of you for being with us. In 2023, we saw yet another year of robust expansion throughout every one of our main customer verticals. Before we wrap up, I'd like to use this moment to express appreciation to our more than 8,000 committed team members, whose work made this achievement possible. Through delivering top-quality, easily reachable care to everyone, you keep demonstrating DocGo's full dedication to democratizing healthcare. I'll keep devoting still more of my time out in the field alongside you, so I can watch you at work, and it's truly inspiring to see the compassion, professionalism, and skilled care that you give to every one of our patients. My gratitude for your remarkable efforts has no end, and I'm proud, I'm proud to be leading a company that's helping transform how healthcare is being delivered for the good. Thanks to you all for joining us, and I look forward to our next report in early May. Be well.
Operator
operatorThank you. That brings us to the end of today’s event, ladies and gentlemen. We appreciate you joining us. You’re welcome to disconnect your lines at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete DocGo Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to DocGo Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DocGo Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.